Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

ClinicalTrials.gov ID: NCT03375047

Public ClinicalTrials.gov record NCT03375047. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).

Study identification

NCT ID: NCT03375047
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sanofi; Industry
Enrollment: 42 participants

Conditions and interventions

Conditions

Cystic Fibrosis

Interventions

MRT5005 Drug
Normal saline Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 10, 2018 (Actual)
Primary completion: Mar 15, 2022 (Actual)
Completion: Mar 15, 2022 (Actual)
Last update posted: Feb 9, 2026

2018 – 2022

United States locations

U.S. sites: 16
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35233	—
National Jewish Health	Denver	Colorado	80206	—
University of Florida	Gainesville	Florida	32610	—
Northwestern University	Chicago	Illinois	60611	—
University of Indiana	Indianapolis	Indiana	46202	—
Maine Medical Center	Portland	Maine	04102	—
Johns Hopkins University	Baltimore	Maryland	21287	—
University of Michigan	Ann Arbor	Michigan	48109	—
University of Cincinnati	Cincinnati	Ohio	45267	—
University Hospitals	Cleveland	Ohio	44106	—
Nationwide Children's Hospital	Columbus	Ohio	43205	—
Oregon Health and Sciences University	Portland	Oregon	97239	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
New Orleans Center for Clinical Research	Knoxville	Tennessee	37920	—
University of Utah	Salt Lake City	Utah	84132	—
Virginia Commonwealth University	Richmond	Virginia	23298	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03375047, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 9, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03375047 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →